Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

This study is observing how bone metastases (cancer that has spread to the bones) respond to targeted drugs called tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer that has specific gene mutations (driver mutations like EGFR, ALK, or ROS1). These mutations can be targeted by specific oral pills, and researchers want to see how bone tumors specifically respond. **You may be eligible if...** - You are between 18 and 100 years old - You have confirmed non-small cell lung cancer with a known actionable driver mutation (such as EGFR, ALK, ROS1, MET, RET, BRAF, or NTRK) - You have bone metastases - You are starting or are already on a targeted therapy (TKI) for your mutation - You are willing to have regular imaging scans of your bones **You may NOT be eligible if...** - Your tumor does not have a targetable driver mutation - You have other cancers that could confuse the bone imaging results - You cannot undergo the required imaging - You are unable to provide informed consent Talk to your doctor to see if this trial is right for you.